The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Strides Pharma Science Ltd

Strides Pharma Science Ltd

BSE 532531 · NSE STAR · ISIN INE939A01011 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹982.45

-0.07%

BSE close, 28 August 2026

Market cap

₹9,055.51 cr

9.2 cr shares · Small cap

Free float

₹6,499.25 cr

as published

P/E · P/B

37.2× · 2.57×

EPS ₹26.39 · BV ₹382.28

FY25-26 rev / PAT

2,180.14 / 183.64

₹ cr, as filed

Filings, window

19

4 selected · 21%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹769.60 52-WK HIGH ₹1,231.45 ₹982.45 46% of range
Against 52-week high-20.2%
Against 52-week low+27.7%
Day change-0.07%
Size bandSmall cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹26.39
Price / earnings37.23×
Price / book2.57×
Book value — derived, price ÷ P/B₹382.28
Return on equity6.92%
Operating margin23.86%
Net margin12.52%

Consistency check

P/B ÷ P/E, which must equal ROE
6.90%
ROE as published
6.92%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 582.65 72.93 7.91 23.86% 12.52%
Mar-26 · Q 605.74 16.35 1.77 12.94% 2.70%
FY25-26 2,180.14 183.64 19.92 18.72% 8.42%

Quarter on quarter

Revenue, quarter on quarter
-3.8%
Net profit, quarter on quarter
+346.1%
Operating margin, quarter on quarter
+1,092 bps

Disclosure profile 19 filings in the window

0 median 17.0 p75 · 25 sector max 52 19 58th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Press Release2
Investor Presentation1
Results1
Selected sub-total4
Procedural
AGM / EGM4
Analyst / Investor Meet3
General2
Annual Report1
BRSR1
Board Meeting1
Compliance Certificate1
Record Date1
Trading Window1
Procedural sub-total15
Total19

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

19 filings · 4 selected · busiest 2026-07-21 and 2026-07-31

Filing rhythm · the twelve most recent

2026-07-312026-10-07

SelectedProcedural

Filings

19 in the window · 4 earlier on record

  1. 7 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 24 September 2026 ·

    Trading Window

    Closure of Trading Window

    Closure of Trading Window for the quarter ended September 30, 2026

    Insider Trading / SAST / Closure of Trading Window View filing →

  3. 23 September 2026 ·

    General

    Strides' Sustainability Report For FY26

    Strides' Sustainability Report for FY26

    Company Update / General View filing →

  4. 11 September 2026 ·

    General

    Completion Of USFDA Inspection At The Company's Formulations Facility At Alathur

    Completion of USFDA Inspection at the Company's Formulation Facility at Alathur

    Company Update / General View filing →

  5. 19 August 2026 ·

    Press Release

    Press Release / Media Release

    Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru

    Company Update / Press Release / Media Release View filing →

  6. 18 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results along with Scrutinizers report for 35th AGM.

    AGM/EGM / AGM View filing →

  7. 14 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 35th Annual General Meeting of the Company

    AGM/EGM / AGM View filing →

  8. 3 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

    Company Update / Analyst / Investor Meet View filing →

  9. 31 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY27

    Company Update / Analyst / Investor Meet View filing →

  10. 31 July 2026 ·

    Investor Presentation

    Investor Presentation

    Earnings Presentation for the quarter ended June 30, 2026

    Company Update / Investor Presentation View filing →

  11. 31 July 2026 ·

    Press Release

    Press Release / Media Release

    Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY

    Company Update / Press Release / Media Release View filing →

  12. 31 July 2026 ·

    Results

    Outcome Of Board Meeting Of The Company Held On July 31, 2026

    Outcome of Board Meeting of the Company held on July 31, 2026

    Result / Financial Results View filing →

  13. 24 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026

    Company Update / Analyst / Investor Meet View filing →

  14. 24 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2026, Amongst Other Matters.

    Strides Pharma Science Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited financial ....

    Board Meeting / Board Meeting View filing →

  15. 21 July 2026 ·

    BRSR

    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Report for FY 2026

    Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

  16. 21 July 2026 ·

    AGM / EGM

    Notice Of 35Th Annual General Meeting

    35th Annual General Meeting is scheduled to be held on Friday, August 14, 2026 at 12:15 hrs IST

    AGM/EGM / AGM View filing →

  17. 21 July 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Annual Report for FY 2025-26

    Others / Reg. 34 (1) Annual Report View filing →

  18. 21 July 2026 ·

    AGM / EGM

    Notice Of 35Th Annual General Meeting

    35th Annual General Meeting is scheduled on Friday, August 14, 2026 at 12:15 HRS IST.

    AGM/EGM / AGM View filing →

  19. 20 July 2026 ·

    Record Date

    Company Has Fixed The Record Date For Final Dividend For FY26 As Friday, July 31, 2026

    Company has fixed the Record Date for Final Dividend for FY26 as Friday, July 31, 2026

    Corp. Action / Record Date View filing →

RSS feed for Strides Pharma Science Ltd · the 50 most recent filings